Two years follow-up of an open-label pilot study of treatment with rituximab in patients with early diffuse cutaneous systemic sclerosis

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Acta Clinica Belgica

• Publication date

  2018-03-04

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/17843286.2017.1372244PMID 28891418
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Risk of Venous Thromboembolism after Total Knee Arthroplasty in Patients with Rheumatoid Arthritis

  2016cited by this paper
• Advances in pathogenesis and treatment of systemic sclerosis.

  2016cited by this paper
• Stabilization of Microcirculation in Patients with Early Systemic Sclerosis with Diffuse Skin Involvement following Rituximab Treatment: An Open-label Study

  2016cited by this paper
• Incidences and Risk Factors of Organ Manifestations in the Early Course of Systemic Sclerosis: A Longitudinal EUSTAR Study

  2016cited by this paper
• Specific Antinuclear Antibody Level Changes after B Cell Depletion Therapy in Systemic Sclerosis Are Associated with Improvement of Skin Thickening

  2016cited by this paper
• Breg Cells Are Numerically Decreased and Functionally Impaired in Patients With Systemic Sclerosis

  2015cited by this paper
• Advances in pathogenesis and treatment of systemic sclerosis.

  2015cited by this paper
• Dosage of rituximab in systemic sclerosis: 2‐year results of five cases

  2015cited by this paper
• Reduced type I collagen gene expression by skin fibroblasts of patients with systemic sclerosis after one treatment course with rituximab.

  2015cited by this paper
• B-cells in systemic sclerosis: emerging evidence from genetics to phenotypes

  2015cited by this paper
• Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group

  2014cited by this paper
• Two-year Results of an Open Pilot Study of a 2-treatment Course with Rituximab in Patients with Early Systemic Sclerosis with Diffuse Skin Involvement

  2013cited by this paper
• B cells tell scleroderma fibroblasts to produce collagen

  2013cited by this paper
• An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative

  2013cited by this paper
• 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative

  2013cited by this paper
• B lymphocytes and B-cell activating factor promote collagen and profibrotic markers expression by dermal fibroblasts in systemic sclerosis

  2013cited by this paper
• A systematic overview on the use and relevance of capillaroscopy in systemic sclerosis

  2013cited by this paper
• Assessing microvascular changes in systemic sclerosis diagnosis and management

  2010cited by this paper
• B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial

  2010cited by this paper
• Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study

  2009cited by this paper
• B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis.

  2009cited by this paper
• Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study

  2008cited by this paper
• Altered B lymphocyte function induces systemic autoimmunity in systemic sclerosis.

  2004cited by this paper
• Transforming growth factor β1 gene (HSTGFB1) nucleotide T869C (codon 10) polymorphism is not associated with prevalence or severity of rheumatoid arthritis in a Caucasian population

  2003cited by this paper
• Improvement in skin thickening in systemic sclerosis associated with improved survival.

  2001cited by this paper
• European multicentre study to define disease activity criteria for systemic sclerosis.* II. Identification of disease activity variables and development of preliminary activity indexes

  2001cited by this paper
• Severe organ involvement in systemic sclerosis with diffuse scleroderma.

  2000cited by this paper
• The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time.

  1997cited by this paper
• Guidelines for clinical trials in systemic sclerosis (scleroderma). I. Disease-modifying interventions. The American College of Rheumatology Committee on Design and Outcomes in Clinical Trials in Systemic Sclerosis.

  1995cited by this paper
• Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis.

  1995cited by this paper
• The MOS 36-ltem Short-Form Health Survey (SF-36): III. Tests of Data Quality, Scaling Assumptions, and Reliability Across Diverse Patient Groups

  1994cited by this paper
• A Simple Sequentially Rejective Multiple Test Procedure

  1979cited by this paper
• Skin thickness and collagen content in progressive systemic sclerosis and localized scleroderma.

  1979cited by this paper

• Long-term outcome of autologous haematopoietic stem cell transplantation in patients with systemic sclerosis: a comparison with patients treated with rituximab and with traditional immunosuppressive agents

  2024cites this paper
• Effects of B Cell Depletion by CD19‐Targeted Chimeric Antigen Receptor T Cells in a Murine Model of Systemic Sclerosis

  2023cites this paper
• Efficacy of rituximab on disease activity, severity, and disease-related damage in patients with immunosuppressive-resistant systemic sclerosis

  2023cites this paper
• Flemish network on rare connective tissue diseases (CTD): patient pathways in systemic sclerosis. First steps taken

  2023cites this paper
• Open questions on the management of targeted therapies for the treatment of systemic sclerosis-interstitial lung disease: results of a EUSTAR survey based on a systemic literature review

  2022cites this paper
• Can Antinuclear Antibodies Have a Pathogenic Role in Systemic Sclerosis?

  2022cites this paper
• Rituximab on lung, skin, and joint involvement in patients with systemic sclerosis: A case series study and review of the literature

  2022cites this paper
• Efficacy and safety of rituximab in the treatment of connective tissue disease-related interstitial lung disease

  2021cites this paper
• Is rituximab effective for systemic sclerosis? A systematic review and meta-analysis

  2021cites this paper
• The target on B cells in Systemic Sclerosis: a “midsummer dream” to extinguish inflammation and prevent early disease progression to fibrosis

  2021cites this paper
• On- and off-label use of rituximab in rheumatic diseases

  2021cites this paper
• Systemic sclerosis (scleroderma): remaining challenges

  2021cites this paper
• Efficacy and safety of rituximab therapy in patients with systemic sclerosis disease (SSc): systematic review and meta-analysis

  2021cites this paper
• B cells in systemic sclerosis: from pathophysiology to treatment

  2021cites this paper
• Efficacy and safety of biological drugs in interstitial lung disease associated with connective tissue diseases

  2021cites this paper
• Efficacy and safety of rituximab on lung and skin involvement in systemic sclerosis: a systematic review and metaanalysis

  2021cites this paper
• ВЛИЯНИЕ РИТУКСИМАБА НА ФУНКЦИЮ ПОЧЕК У БОЛЬНЫХ СИСТЕМНОЙ СКЛЕРОДЕРМИЕЙ

  2020cites this paper
• Is biological therapy in systemic sclerosis the answer?

  2020cites this paper
• News and failures from recent treatment trials in systemic sclerosis.

  2020cites this paper
• Expert Perspectives On Clinical Challenges: Expert Perspectives: Challenges in Scleroderma

  2020cites this paper
• Rituximab as a rescue treatment added on mycophenolate mofetil background therapy in progressive systemic sclerosis associated interstitial lung disease unresponsive to conventional immunosuppression.

  2020cites this paper
• Rituximab in the Treatment of Interstitial Lung Disease Associated with Autoimmune Diseases: Experience from a Single Referral Center and Literature Review

  2020cites this paper
• Infections and systemic sclerosis: an emerging challenge

  2020cites this paper
• Safety of Newer Disease Modifying Therapies in Multiple Sclerosis

  2020cites this paper
• Infecciones y esclerosis sistémica: un desafío emergente

  2020cites this paper
• Short-term absolute B-cell counts monitoring in systemic sclerosis patients treated with rituximab

  2020cites this paper
• Safety and efficacy of Rituximab in systemic sclerosis: A systematic review and meta-analysis.

  2019cites this paper
• Targeting CD20 in the treatment of interstitial lung diseases related to connective tissue diseases: A systematic review.

  2019cites this paper
• Skin improvement is a surrogate for favourable changes in other organ systems in early diffuse cutaneous systemic sclerosis.

  2019cites this paper
• A protocol for systematic review

  2019influential citation
• Changes in skin score in early diffuse cutaneous systemic sclerosis are associated with changes in global disease severity.

  2019cites this paper
• Targeting very early systemic sclerosis: a case-based review

  2019cites this paper
• Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study

  2019cites this paper
• One year in review 2018: systemic sclerosis.

  2018cites this paper
• Rituximab in systemic autoimmune rheumatic diseases: indications and practical use

  2018cites this paper
• Targeting TLRs and the inflammasome in systemic sclerosis

  2018cites this paper
• Efficacy and safety of rituximab in systemic sclerosis: French retrospective study and literature review.

  2018cites this paper
• Combination of 5‐aminolevulinic acid and iron prevents skin fibrosis in murine sclerodermatous graft‐versus‐host disease

  2018cites this paper
• Systematic review of the role of rituximab in treatment of antineutrophil cytoplasmic autoantibody-associated vasculitis, hepatitis C virus-related cryoglobulinemic vasculitis, Henoch–Schönlein purpura, ankylosing spondylitis, and Raynaud’s phenomenon

  2017cites this paper